Abstract:INTRODUCTION: The relationships between body mass index (BMI) and survival rates are complex, and have not been thoroughly investigated in breast cancer patients who received adjuvant chemotherapy.METHODS: We collected data on 2394 patients from two randomized, phase III clinical trials that investigated adjuvant chemotherapy in breast cancer identified in Project Data Sphere. The objective was to examine the effect of baseline BMI, BMI after adjuvant chemotherapy, and BMI change from baseline to post-adjuvant chemotherapy on disease-free survival (DFS) and overall survival (OS). Restricted cubic splines were used to examine potential non-linear associations between continuous BMI value and survival. Stratified analyses involved chemotherapy regimens.RESULTS: Severe obesity (BMI≥40.0 kg/m<sup>2</sup>) at baseline was independently associated with worse DFS (hazard ration [HR] = 1.48, 95% confidence interval [CI] 1.02-2.16, P = 0.04) and OS (HR = 1.79, 95%CI 1.17-2.74, P = 0.007) compared with underweight/normal weight (BMI≤24.9 kg/m<sup>2</sup>). A BMI loss >10% was also an independent prognostic factor for adverse OS (HR = 2.14, 95%CI 1.17-3.93, P = 0.014). Stratified analyses revealed that severe obesity adversely affected DFS (HR = 2.38, 95%CI 1.26-4.34, P = 0.007) and OS (HR = 2.90, 95%CI 1.46-5.76, P = 0.002) in the docetaxel-based group, but not in the non-docetaxel-based group. Restricted cubic splines revealed a "J-shaped" association of baseline BMI with risk of recurrence or all-cause death, and this relationship was more pronounced in the docetaxel-based group.CONCLUSIONS: In early breast cancer patients treated with adjuvant chemotherapy, baseline severe obesity was significantly linked to worse DFS and OS, and a BMI loss over 10% from baseline to post-adjuvant chemotherapy also negatively affected OS. Moreover, the prognostic role of BMI might differ between docetaxel-based and non-docetaxel-based groups.

Higher body mass index indicated better overall survival in pancreatic ductal adenocarcinoma patients: a real-world study of 2010 patients

Higher BMI Indicated Better Overall Survival Prognosis of Pancreatic Ductal Adenocarcinoma: A Real-World Study Based on 2,010 Cases

The Prognostic Impact of Body Mass Index in Patients with Diffuse Large B-Cell Lymphoma: A Meta-Analysis.

Body Mass Index at Diagnosis is Associated with Survival Outcome in Peripheral T-cell Lymphoma: a Study of Chinese Population

Effect of Body Mass Index on Overall Survival of Pancreatic Cancer

Positive Effect of Higher Adult Body Mass Index on Overall Survival of Digestive System Cancers Except Pancreatic Cancer: A Systematic Review and Meta-Analysis

Body mass index in relation to ovarian cancer survival.

Body Mass Index and Survival after Cancer Diagnosis: A Pan-Cancer Cohort Study of 114 430 Patients with Cancer

Beneficial Body Mass Index to Enhance Survival Outcomes in Patients with Early-Stage Hepatocellular Carcinoma Following Microwave Ablation Treatment

239MO Impact of Body Mass Index and Its Change on Survival Outcomes in Patients with Early Breast Cancer: A Pooled Analysis of Individual-Level Data from BCIRG-001 and BCIRG-005 Trials

Impact of body mass index and its change on survival outcomes in patients with early breast cancer: A pooled analysis of individual-level data from BCIRG-001 and BCIRG-005 trials

The Prognostic Role of Obesity is Independent of Sex in Cancer Patients Treated with Immune Checkpoint Inhibitors: A Pooled Analysis of 4090 Cancer Patients.

Impact of Body Mass Index on Survival of Esophageal Squamous Carcinoma Patients in Southern China.

The Predictive Value of Body Mass Index on Prognosis and Adverse Events of Cancers Treated with Immunotherapy: a Systematic Review and Meta-Analysis

Association between body mass index and survival outcomes for patients with advanced non–small-cell lung cancer treated with immune checkpoint inhibitors: A systematic review and meta-analysis.

Association Between Body Mass Index and Survival Outcomes In Patients Treated With Immune Checkpoint Inhibitors: Meta-analyses of Individual Patient Data

Body Mass Index (BMI) May Be a Prognostic Factor for Gastric Cancer with Peritoneal Dissemination

Evaluation of the Body Mass Index in Breast Cancer Prognosis in a Cohort of Small-Stature Overweight Patients: Multi-Center Study in China

The Relationship Between Body Mass Index Changes During Chemotherapy and Prognosis of Patients with Advanced Colorectal Cancer: A Retrospective Cohort Study

Body mass index, as a novel predictor of hepatocellular carcinoma patients treated with Anti-PD-1 immunotherapy

Prediagnosis Body Mass Index and Waist–hip Circumference Ratio in Association with Colorectal Cancer Survival